The results described in Cell Reports underscore the value of the single cell method to
evaluate tumor therapy.
Not exact matches
Several ongoing projects include the identification of newly discovered gene rearrangements in rare and refractory (unresponsive or resistant to
therapy)
tumors from patients
evaluated at the Rutgers Cancer Institute of New Jersey.
My goal is to understand how and why a person may or may not respond to
therapy by
evaluating certain markers — genetic changes, proteins, and other features — in blood or
tumor tissue.
Patients receive a personalized, comprehensive approach to care for their benign and malignant brain
tumors and are
evaluated for multimodality treatments such as chemotherapy, minimally invasive surgical options, and radiation
therapy including proton
therapy and gamma knife.